STREPTOMYCIN SULFATE

First approved in 1946

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C21H39N7O12.3H2O4S
Molecular Weight	1457.384
Optical Activity	UNSPECIFIED
Defined Stereocenters	30 / 30
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@H]2[C@H](O[C@H]3[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]3NC(N)=N)O[C@@H](C)[C@]2(O)C=O.CN[C@H]4[C@H](O)[C@@H](O)[C@H](CO)O[C@H]4O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](NC(N)=N)[C@@H](O)[C@@H]6NC(N)=N)O[C@@H](C)[C@]5(O)C=O

InChI

InChIKey=QTENRWWVYAAPBI-YCRXJPFRSA-N

InChI=1S/2C21H39N7O12.3H2O4S/c2*1-5-21(36,4-30)16(40-17-9(26-2)13(34)10(31)6(3-29)38-17)18(37-5)39-15-8(28-20(24)25)11(32)7(27-19(22)23)12(33)14(15)35;3*1-5(2,3)4/h2*4-18,26,29,31-36H,3H2,1-2H3,(H4,22,23,27)(H4,24,25,28);3*(H2,1,2,3,4)/t2*5-,6-,7+,8-,9-,10-,11+,12-,13-,14+,15+,16-,17-,18-,21+;;;/m00.../s1

HIDE SMILES / InChI

Molecular Formula	C21H39N7O12
Molecular Weight	581.5741
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	15 / 15
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	H2O4S
Molecular Weight	98.078
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB01082
Curator's Comment: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf

Streptomycin is a water-soluble aminoglycoside derived from Streptomyces griseus. Aminoglycosides work by binding to the bacterial 30S ribosomal subunit, causing misreading of t-RNA, leaving the bacterium unable to synthesize proteins vital to its growth. Aminoglycosides are useful primarily in infections involving aerobic, Gram-negative bacteria, such as Pseudomonas, Acinetobacter, and Enterobacter. In addition, some mycobacteria, including the bacteria that cause tuberculosis, are susceptible to aminoglycosides. Infections caused by Gram-positive bacteria can also be treated with aminoglycosides, but other types of antibiotics are more potent and less damaging to the host. In the past the aminoglycosides have been used in conjunction with penicillin-related antibiotics in streptococcal infections for their synergistic effects, particularly in endocarditis. Aminoglycosides are mostly ineffective against anaerobic bacteria, fungi and viruses. Aminoglycosides like Streptomycin "irreversibly" bind to specific 30S-subunit proteins and 16S rRNA. Specifically Streptomycin binds to four nucleotides of 16S rRNA and a single amino acid of protein S12. This interferes with decoding site in the vicinity of nucleotide 1400 in 16S rRNA of 30S subunit. This region interacts with the wobble base in the anticodon of tRNA. This leads to interference with the initiation complex, misreading of mRNA so incorrect amino acids are inserted into the polypeptide leading to nonfunctional or toxic peptides and the breakup of polysomes into nonfunctional monosomes. Streptomycin is indicated for the treatment of tuberculosis. May also be used in combination with other drugs to treat tularemia (Francisella tularensis), plague (Yersia pestis), severe M. avium complex, brucellosis, and enterococcal endocarditis (e.g. E. faecalis, E. faecium).

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Ribosome 11 Target ID: map03010 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17967466 \| http://www.genome.jp/dbget-bin/www_bget?dr:D01350	Inhibitor 8504
Mycobacterium tuberculosis 21 Target ID: CHEMBL360 Sources: https://www.ncbi.nlm.nih.gov/pubmed/27135906	Inhibitor 8504	5.36 µM [IC50]
Francisella tularensis subsp. tularensis SCHU S4 5 Target ID: CHEMBL612748 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23065699	Inhibitor 8504

Conditions

Condition	Modality	Highest Phase	Product
Tuberculosis 83 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf	Curative	Approved 8583	STREPTOMYCIN SULFATE Approved Use Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1946
Plague 14 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf	Curative	Approved 8583	STREPTOMYCIN SULFATE Approved Use Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1946
Tularemia 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf	Curative	Approved 8583	STREPTOMYCIN SULFATE Approved Use Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1946
Chancroid 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/064210s009lbl.pdf	Curative	Approved 8583	STREPTOMYCIN SULFATE Approved Use Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Pasteurella pestis (plague), Francisella tularensis (tularemia), Brucella, Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans, Enterococcus faecalis (in endocardial infections -concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1946

C_max

Value	Dose	Co-administered	Analyte	Population
42.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560193/	18 mg/kg single, intramuscular dose: 18 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:		STREPTOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
264 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560193/	18 mg/kg single, intramuscular dose: 18 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:		STREPTOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.67 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/11560193/	18 mg/kg single, intramuscular dose: 18 mg/kg route of administration: Intramuscular experiment type: SINGLE co-administered:		STREPTOMYCIN plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8540716	unhealthy, 12–70 Health Status: unhealthy Age Group: 12–70 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8540716	Disc. AE: Heartburn, Fatigue... AEs leading to discontinuation/dose reduction: Heartburn (1.06%) Fatigue (1.06%) Sources: https://pubmed.ncbi.nlm.nih.gov/8540716
1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6989067	unhealthy, 15-70 Health Status: unhealthy Age Group: 15-70 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6989067	Disc. AE: Hypersensitivity, Disorder vestibular... AEs leading to discontinuation/dose reduction: Hypersensitivity (1.7%) Disorder vestibular (0.84%) Sources: https://pubmed.ncbi.nlm.nih.gov/6989067
1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	Other AEs: Ototoxicity, Nephrotoxicity... Other AEs: Ototoxicity Nephrotoxicity Vestibular toxicity Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	Other AEs: Ototoxicity, Nephrotoxicity... Other AEs: Ototoxicity Nephrotoxicity Vestibular toxicity Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 26–73 Health Status: unhealthy Age Group: 26–73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	Other AEs: Ototoxicity, Nephrotoxicity... Other AEs: Ototoxicity Nephrotoxicity Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 26–73 Health Status: unhealthy Age Group: 26–73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	Other AEs: Ototoxicity, Nephrotoxicity... Other AEs: Ototoxicity Nephrotoxicity Sources: https://pubmed.ncbi.nlm.nih.gov/15156439

AEs

AE	Significance	Dose	Population
Fatigue	1.06% Disc. AE	1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8540716	unhealthy, 12–70 Health Status: unhealthy Age Group: 12–70 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8540716
Heartburn	1.06% Disc. AE	1 g 1 times / day multiple, intramuscular Recommended Dose: 1 g, 1 times / day Route: intramuscular Route: multiple Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/8540716	unhealthy, 12–70 Health Status: unhealthy Age Group: 12–70 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/8540716
Disorder vestibular	0.84% Disc. AE	1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6989067	unhealthy, 15-70 Health Status: unhealthy Age Group: 15-70 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6989067
Hypersensitivity	1.7% Disc. AE	1 g 1 times / day steady, intravenous Recommended Dose: 1 g, 1 times / day Route: intravenous Route: steady Dose: 1 g, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/6989067	unhealthy, 15-70 Health Status: unhealthy Age Group: 15-70 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/6989067
Nephrotoxicity		1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Ototoxicity		1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Vestibular toxicity		1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Nephrotoxicity		1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Ototoxicity		1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Vestibular toxicity		1225 mg 3 times / week steady, intravenous Recommended Dose: 1225 mg, 3 times / week Route: intravenous Route: steady Dose: 1225 mg, 3 times / week Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 25–76 Health Status: unhealthy Age Group: 25–76 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Nephrotoxicity		800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 26–73 Health Status: unhealthy Age Group: 26–73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Ototoxicity		800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 26–73 Health Status: unhealthy Age Group: 26–73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Nephrotoxicity		800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 26–73 Health Status: unhealthy Age Group: 26–73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439
Ototoxicity		800 mg 1 times / day steady, intravenous Recommended Dose: 800 mg, 1 times / day Route: intravenous Route: steady Dose: 800 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/15156439	unhealthy, 26–73 Health Status: unhealthy Age Group: 26–73 Sex: M+F Sources: https://pubmed.ncbi.nlm.nih.gov/15156439

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
OATP1B1 1079 OATP2B1 157 OATP1B3 961

Drug as perpetrator

Target	Modality	Activity
OATP1B1 1095	inhibitor 4027 Sources: https://aac.asm.org/content/aac/60/5/3096.full.pdf#page=6 Page: 6.0	not determined
OATP1B3 970	inhibitor 4027 Sources: https://aac.asm.org/content/aac/60/5/3096.full.pdf#page=6 Page: 6.0	not determined
OATP2B1 162	inhibitor 4027 Sources: https://aac.asm.org/content/aac/60/5/3096.full.pdf#page=6 Page: 6.0	yes [IC50 33.2 uM]

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:17076	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:17076
ChemicalBook	CB3462887	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3462887
MolPort	MolPort-002-525-998	https://www.molport.com/shop/molecule-link/MolPort-002-525-998
ZINC	ZINC000008214681	http://zinc15.docking.org/substances/ZINC000008214681

PubMed

Title	Date	PubMed
Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.	2008-08-05	18684007
Effect of attenuation of Treg during BCG immunization on anti-mycobacterial Th1 responses and protection against Mycobacterium tuberculosis.	2008-07-30	18665224
Mouse hepatitis coronavirus RNA replication depends on GBF1-mediated ARF1 activation.	2008-06-13	18551169
Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways.	2008-06-10	18544167
Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis.	2008-06-05	18577264
Human IL-12 p40 as a reporter gene for high-throughput screening of engineered mouse embryonic stem cells.	2008-06-03	18522747
In infertile women, cells from Chlamydia trachomatis infected sites release higher levels of interferon-gamma, interleukin-10 and tumor necrosis factor-alpha upon heat-shock-protein stimulation than fertile women.	2008-05-20	18489796
The effect of radio-adaptive doses on HT29 and GM637 cells.	2008-04-23	18433479
Mucosal damage and neutropenia are required for Candida albicans dissemination.	2008-02-08	18282097
Genomic organization, sequence divergence, and recombination of feline immunodeficiency virus from lions in the wild.	2008-02-05	18251995
(R)-albuterol decreases immune responses: role of activated T cells.	2008-01-14	18194569
Regulation of glycogen synthase kinase 3beta functions by modification of the small ubiquitin-like modifier.	2008	18949077
Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity.	2008	18946510
Receptor-induced thiolate couples Env activation to retrovirus fusion and infection.	2007-12-21	18260686
Full-exon resequencing reveals toll-like receptor variants contribute to human susceptibility to tuberculosis disease.	2007-12-19	18091991
Purification of infectious human herpesvirus 6A virions and association of host cell proteins.	2007-10-19	17949490
Gentamicin suppresses endotoxin-driven TNF-alpha production in human and mouse proximal tubule cells.	2007-10	17699551
Selective damage of the vestibular apparatus following toxic effects of streptomycin.	2007-07	17599591
Effect and mechanism of lipopolysaccharide on allergen-induced interleukin-5 and eotaxins production by whole blood cultures of atopic asthmatics.	2007-03	17302892
Resistance of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis to nitric oxide correlates with disease severity in Tegumentary Leishmaniasis.	2007-02-22	17316450
ArhGAP9, a novel MAP kinase docking protein, inhibits Erk and p38 activation through WW domain binding.	2007-02-06	17284314
Interaction between Bluetongue virus outer capsid protein VP2 and vimentin is necessary for virus egress.	2007-01-15	17224050
Identification of putative cis-regulatory elements in Cryptosporidium parvum by de novo pattern finding.	2007-01-09	17212834
Inhibition of NF-kappaB activation in vivo impairs establishment of gammaherpesvirus latency.	2007-01	17257062
Dexamethasone stimulates expression of C-type Natriuretic Peptide in chondrocytes.	2006-11-20	17116261
Activity of 7-methyljuglone in combination with antituberculous drugs against Mycobacterium tuberculosis.	2006-11	16987644
Time- and concentration-dependent changes in gene expression induced by benzo(a)pyrene in two human cell lines, MCF-7 and HepG2.	2006-10-16	17042939
Antituberculous therapy-induced fulminant hepatic failure: successful treatment with liver transplantation and nonstandard antituberculous therapy.	2006-09	16933231
Endostatin inhibits VEGF-A induced osteoclastic bone resorption in vitro.	2006-07-13	16839420
Enhanced susceptibility of multidrug resistant strains of Mycobacterium tuberculosis to granulysin peptides correlates with a reduced fitness phenotype.	2006-07	16793311
Insulin-like growth factor-1 (IGF-1) induces the activation/phosphorylation of Akt kinase and cAMP response element-binding protein (CREB) by activating different signaling pathways in PC12 cells.	2006-06-22	16792806
Hearing impairment in patients with tuberculosis from Northeast Brazil.	2006-05-16	16699632
Streptomycin action to the mammalian inner ear vestibular organs: comparison between pigmented guinea pigs and rats.	2006-04-28	17011831
Rapid microbiologic and pharmacologic evaluation of experimental compounds against Mycobacterium tuberculosis.	2006-04	16569835
[Isoniazid-induced visual hallucinosis].	2006-03	16550135
Fluoroquinolones: an important class of antibiotics against tuberculosis.	2006	16475933
Neogenin expression may be inversely correlated to the tumorigenicity of human breast cancer.	2005-12-03	16324219
Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates.	2005-11	16251329
Is liver transplantation advisable for isoniazid fulminant hepatitis in active extrapulmonary tuberculosis?	2005-11	16212643
Signaling of the Human P2Y(1) Receptor Measured by a Yeast Growth Assay with Comparisons to Assays of Phospholipase C and Calcium Mobilization in 1321N1 Human Astrocytoma Cells.	2005-09	16467903
Antimycobacterial agents differ with respect to their bacteriostatic versus bactericidal activities in relation to time of exposure, mycobacterial growth phase, and their use in combination.	2005-06	15917538
Intracellular localization of Crimean-Congo Hemorrhagic Fever (CCHF) virus glycoproteins.	2005-04-25	15850490
Cloning of the koi herpesvirus (KHV) gene encoding thymidine kinase and its use for a highly sensitive PCR based diagnosis.	2005-03-17	15774009
Unbiased quantification of Scarpa's ganglion neurons in aminoglycoside ototoxicity.	2005	16286701
Synthesis, antimicrobial activity and molecular modeling studies of halogenated 4-[1H-imidazol-1-yl(phenyl)methyl]-1,5-diphenyl-1H-pyrazoles.	2004-10-15	15388173
The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems.	1992-05	1624388
[A case of pulmonary tuberculosis associated with severe skin eruption, prominent eosinophilia, and liver dysfunction induced by streptomycin].	1992-05	1534589
Oxazolidinones, a new class of synthetic antituberculosis agent. In vitro and in vivo activities of DuP-721 against Mycobacterium tuberculosis.	1991-11-01	1802533
A method for evaluating antitubercular activity in mice.	1949-12-14	15408463
The evaluation of neomycin and other antimicrobial agents of bacterial and fungal origin, and substances from higher plants.	1949-12-14	15398785

Patents

Sample Use Guides

In Vivo Use Guide

Intramuscular Route Only Adults: The preferred site is the upper outer quadrant of the buttock, (i.e., gluteus maximus), or themid-lateral thigh. Children: It is recommended that intramuscular injections be given preferably in the mid-lateral muscles of the thigh. In infants and small children the periphery of the upper outer quadrant of the gluteal region should be used only when necessary, such as in burn patients, in order to minimize the possibility of damage to the sciatic nerve. 1. TUBERCULOSIS: Children daily - 20-40 mg/kg Adults daily - 15 mg/kg Streptomycin is usually administered daily as a single intramuscular injection. A total dose of not more than 120 g over the course of therapy should be given unless there are no other therapeutic options. 2. TULAREMIA: One to 2 g daily in divided doses for 7 to 14 days until the patient is afebrile for 5 to 7 days. 3. PLAGUE: Two grams of Streptomycin daily in two divided doses should be administered intramuscularly. A minimum of 10 days of therapy is recommended. 4. BACTERIAL ENDOCARDITIS: a. Streptococcal endocarditis; in penicillin-sensitive alpha and non-hemolytic streptococcal endocarditis (penicillin MIC<0.1 mcg/mL), Streptomycin may be used for 2-week treatment concomitantly with penicillin. The Streptomycin regimen is 1 g b.i.d. for the first week, and 500 mg b.i.d. for the second week. If the patient is over 60 years of age, the dosage should be 500 mg b.i.d. for the entire 2- week period. b. Enterococcal endocarditis: Streptomycin in doses of 1 g b.i.d. for 2 weeks and 500 mg b.i.d. for an additional 4 weeks is given in combination with penicillin. Ototoxicity may require termination of the Streptomycin prior to completion of the 6-week course of treatment. 5. CONCOMITANT USE WITH OTHER AGENTS: For concomitant use with other agents to which the infecting organism is also sensitive: Streptomycin is considered a secondline agent for the treatment of gram-negative bacillary bactermia, meningitis, and pneumonia; brucellosis; granuloma inguinale; chancroid, and urinary tract infection. For adults: 1 to 2 grams in divided doses every six to twelve hours for moderate to severe infections. Doses should generally not exceed 2 grams per day. For children: 20 to 40 mg/kg/day (8 to 20 mg/lb/day) in divided doses every 6 to 12 hours. (Particular care should be taken to avoid excessive dosage in children).

Route of Administration: Intramuscular

In Vitro Use Guide

At 5 and 50 ug/ml, streptomycin inhibited the tubercle bacilli strongly and killed some; at the lowest tested concentration of 0.5 ug/ml, it inhibited them weakly.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:02:32 GMT 2025` Edited by `admin` on `Mon Mar 31 18:02:32 GMT 2025`
Record UNII	CW25IKJ202
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

STREPTOMYCIN SULFATE

Common Name

English

NSC-757316

Preferred Name

English

STREPTOMYCIN SULFATE [ORANGE BOOK]

Common Name

English

STRYCIN

Common Name

English

STREPTOMYCIN SULFATE [VANDF]

Common Name

English

STREPTOMYCIN SULFATE (NON-INJECTABLE) [WHO-IP]

Common Name

English

D-STREPTAMINE, O-2-DEOXY-2-(METHYLAMINO)-.ALPHA.-L-GLUCOPYRANOSYL-(1->2)-O-5-DEOXY-3-C-FORMYL-.ALPHA.-L-LYXOFURANOSYL-(1->4)-N,N'-BIS(AMINOIMINOMETHYL)-, SULFATE (2:3) (SALT)

Common Name

English

AGRIMYCIN SULFATE

Common Name

English

STREPTOMYCIN SULFATE [MART.]

Common Name

English

STREPTOMYCIN SULFATE [USP MONOGRAPH]

Common Name

English

STREPTOMYCIN SULFATE [JAN]

Common Name

English

STREPTOMYCIN (AS SULFATE)

Common Name

English

VETSTREP

Common Name

English

STREPTOMYCIN SULFATE [EP MONOGRAPH]

Common Name

English

STREPTOMYCIN SULPHATE

Common Name

English

STREPTOMYCIN SULFATE [USP-RS]

Common Name

English

STREPTOMYCIN SULPHATE (2:3) (SALT)

Common Name

English

STREPTOMYCINI SULFAS [WHO-IP LATIN]

Common Name

English

Streptomycin sulfate [WHO-DD]

Common Name

English

STREPTOMYCIN SULFATE [WHO-IP]

Common Name

English

D-STREPTAMINE, O-2-DEOXY-2-(METHYLAMINO)-.ALPHA.-L-GLUCOPYRANOSYL-(1->2)-O-5-DEOXY-3-C-FORMYL-.ALPHA.-L-LYXOFURANOSYL-(1->4)-N,N'-BIS(AMINOIMINOMETHYL)-, SULPHATE (2:3) (SALT)

Common Name

English

AGRIMYCIN 17

Common Name

English

STREPTOMYCIN SULFATE [GREEN BOOK]

Common Name

English

STREPTOMYCIN SESQUISULFATE [MI]

Common Name

English

AMBISTRYN S

Common Name

English

Streptomycin sulfate (2:3) (salt)

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2363